Browsing Radiotherapy and Imaging by author "van As, Nick"
Now showing items 1-7 of 7
-
Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
De Bleser, E; Jereczek-Fossa, BA; Pasquier, D; Zilli, T; Van As, N; et al. (2019-12)Background Stereotactic body radiotherapy (SBRT) and elective nodal radiotherapy (ENRT) are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer (PC); however, comparative data are still ... -
MRI-guided prostate adaptive radiotherapy - A systematic review.
McPartlin, AJ; Li, XA; Kershaw, LE; Heide, U; Kerkmeijer, L; et al. (2016-06)Dose escalated radiotherapy improves outcomes for men with prostate cancer. A plateau for benefit from dose escalation using EBRT may not have been reached for some patients with higher risk disease. The use of increasingly ... -
Pan-cancer analysis of whole genomes.
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, (NATURE PORTFOLIO, 2020-02-06)Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1-3. Here we report the integrative analysis of ... -
Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
Ost, P; Jereczek-Fossa, BA; Van As, N; Zilli, T; Tree, A; et al.Aims To report the relapse pattern of stereotactic body radiotherapy (SBRT) for oligorecurrent nodal prostate cancer (PCa).Materials and methods PCa patients with ≤3 lymph nodes (N1/M1a) at the time of recurrence were ... -
Reply from Authors re: Tillmann Loch, Pat Fox Fulgham. Active Surveillance Challenges in Men with Prostate Cancer: Role of Imaging Today and Tomorrow. Eur Urol 2016;69:1034-6: Imaging in Active Surveillance for Prostate Cancer: Where Should We Focus Our Research?
Henderson, DR; de Souza, NM; Parker, CC; van As, NJ (2016-06) -
Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus.
Jereczek-Fossa, BA; Marvaso, G; Zaffaroni, M; Gugliandolo, SG; Zerini, D; et al.<h4>Background and purpose</h4>Between 30% and 47% of patients treated with definitive radiotherapy (RT) for prostate cancer are at risk of intraprostatic recurrence during follow-up. Re-irradiation with stereotactic body ... -
UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.
Hanna, GG; Murray, L; Patel, R; Jain, S; Aitken, KL; et al. (2018-01)Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management ...